AMRA Medical assessed adverse muscle composition within obesity and its impact on functional performance and metabolic comorbidity and will digitally present the results at the congress.
Linköping, Sweden, September 3, 2020: AMRA, in partnership with Linköping University, utilized magnetic resonance imaging (MRI) to identify associations between adverse muscle composition (AMC), functional performance, and metabolic comorbidities in patients with obesity and will share the results at the European and International Congress on Obesity 2020, 1-4 September.
The research was based on 9,612 UK Biobank participants and assessed the impact of AMC on metabolic health and functional performance in obesity. AMRA specifically quantified fat-free muscle volume and muscle fat infiltration using AMRA® Researcher. Each participant was then given a personalized muscle volume z-score, calculated using virtual control groups1, which was combined with muscle fat infiltration for AMC detection. Prevalence of low functional performance (e.g. slow walking pace and hand grip strength) and metabolic comorbidity (coronary heart disease (CHD), diabetes type 2 (DT2)) in participants with obesity and AMC were compared to those with obesity without AMC.
AMRA researchers found that although a majority of individuals with obesity presented with normal muscle composition, AMC was detected in as many as 17% of those with obesity. This group showed a significantly higher prevalence of low functional performance. Interestingly, the prevalence of CHD, and DT2 was also significantly higher in those with AMC. The results indicate that maintaining and tracking muscle health is of high importance for patients with obesity. Differentiating muscle composition between patients also offer researchers objective clinical measurements for assessing sarcopenia, which is underestimated in obesity.
AMRA will virtually present “Adverse Muscle Composition within Obesity is Associated with Increased Metabolic Comorbidity and Low Functional Performance – Results from the Large UK Biobank Imaging Study” at ECOICO online during Physical Activity – Impact for Weight Management Session (ROOM 3) on Friday, 4 September at 10:00-10:10 am CEST.
Learn more about AMRA’s research, capabilities, and opportunities for collaboration by attending AMRA’s digital poster presentation at ECOICO 2020 and visiting www.amramedical.com.
About AMRA Medical
AMRA is a ground-breaking international digital health company at the forefront of medical imaging and precision medicine. The company has developed a new global standard in body composition assessment, the ability to automatically produce multiple fat and muscle biomarkers with unrivaled precision and accuracy, as well as contextual disease insights – all from a single, rapid, whole-body MRI. AMRA’s aim is to support transformative care and vital decision-making from clinical research to health and wellness.
SVP Global BD & Marketing
1Linge et al, J Gerontol A Biol Sci Med Sci 2020. doi: 10.1093/gerona/glz229